Studies risk factors for liver inflammation and scarring in hepatitis B with fatty liver
Observes adults with hepatitis B and fatty liver to find factors linked to liver damage.
Plain-language title generated from the registry record
Registry title: Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With CHB and NAFLD
Key facts
- Where
- Nanjing, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with long-term hepatitis B who also have non-alcoholic fatty liver disease. It studies what raises the risk of liver inflammation, scarring and later liver problems.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Chronic hepatitis B together with non-alcoholic fatty liver disease (NAFLD). NAFLD is shown by imaging, liver biopsy, and/or blood tests or predictive indices.
- Biomarker or test result
- Hepatitis B surface antigen (HBsAg) positive for at least 6 months, with no other viral co-infection at the start.
Main reasons for not taking part
- Other chronic liver diseases, such as alcoholic liver disease, other viral hepatitis or drug-induced liver injury
- Liver cancer (HCC) or another cancer before the liver biopsy
Read by machine on 12 November 2026.
Where in China
- Nanjing Drum Tower hospitalNanjing, ChinaContact: Jie LiTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Trial code
- NCT05766449
- Record updated
- 13 March 2023
- Original description
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major global public health issue.Meanwhile, with the improvement of living standards and changes in lifestyle and dietary habits, non-alcoholic fatty liver disease (NAFLD) has become another important cause of liver cirrhosis and HCC.HBV combined with NAFLD inevitably develops into continuous or intermittent liver inflammation and fibrosis, which greatly increases the risk of cirrhosis, liver cancer and even end-stage liver disease. We aimed to investigate the risk factors and establish diagnostic models for hepatic inflammation, fibrosis in patients with CHB associated NAFLD. In addition, to find risk factors for liver cirrhosis, liver cancer or liver failure in patients with CHB-related NAFLD.Read full original descriptionShow less
Risk Factors for Hepatic Inflammation, Fibrosis and Prognosis in Patients With Chronic Hepatitis B Combined With Non-alcoholic Fatty Liver Disease
Chronic hepatitis B (CHB) affects an estimated 292 million people, and causes approximately 800,000 people deaths per year from liver-related complications including cirrhosis and hepatocellular carcinoma, remaining a major global public health issue.Meanwhile, with the improvement of living standards and changes in lifestyle and dietary habits, non-alcoholic fatty liver disease (NAFLD) has become another important cause of liver cirrhosis and HCC.HBV combined with NAFLD inevitably develops into continuous or intermittent liver inflammation and fibrosis, which greatly increases the risk of cirrhosis, liver cancer and even end-stage liver disease. We aimed to investigate the risk factors and establish diagnostic models for hepatic inflammation, fibrosis in patients with CHB associated NAFLD. In addition, to find risk factors for liver cirrhosis, liver cancer or liver failure in patients with CHB-related NAFLD.
Inclusion: 1.18 years or older 2. Positive hepatitis B surface antigen (HBsAg) for at least 6 months and without other viral co-infection at baseline 2.NAFLD diagnosed by imaging liver biopsy, and/or blood testing/predictive indices.
Exclusion: Other chronic liver diseases, such as alcoholic liver disease, other viral hepatitis, drug-induced liver injury; HCC or other malignancies before liver biopsy.